Mild COVID-19 infection does not alter the ovarian reserve in women treated with ART.
AMH
ART
COVID
Ovarian reserve
Journal
Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
23
06
2021
revised:
25
08
2021
accepted:
01
09
2021
pubmed:
30
10
2021
medline:
17
12
2021
entrez:
29
10
2021
Statut:
ppublish
Résumé
Does mild COVID-19 infection affect the ovarian reserve of women undergoing an assisted reproductive technology (ART) protocol? A prospective observational study was conducted between June and December 2020 at the ART unit of Tenon Hospital, Paris. Women managed at the unit for fertility issues by in-vitro fecundation, intracytoplasmic sperm injection (IVF/ICSI), fertility preservation, frozen embryo transfer or artificial insemination, and with an anti-Müllerian hormone (AMH) test carried out within 12 months preceding ART treatment, were included. All the women underwent a COVID rapid detection test (RDT) and AMH concentrations between those who tested positive (RDT positive) and those who tested negative (RDT negative). The study population consisted of 118 women, 11.9% (14/118) of whom were COVID RDT positive. None of the tested women presented with a history of severe COVID-19 infection. The difference between the initial AMH concentration and AMH concentration tested during ART treatment was not significantly different between the COVID RDT positive group and COVID RDT negative group (-1.33 ng/ml [-0.35 to -1.61) versus -0.59 ng/ml [-0.15 to -1.11], P = 0.22). A history of mild COVID-19 infection does not seem to alter the ovarian reserve as evaluated by AMH concentrations. Although these results are reassuring, further studies are necessary to assess the effect of COVID-19 on pregnancy outcomes in women undergoing ART.
Identifiants
pubmed: 34711516
pii: S1472-6483(21)00431-4
doi: 10.1016/j.rbmo.2021.09.001
pmc: PMC8432972
pii:
doi:
Substances chimiques
Anti-Mullerian Hormone
80497-65-0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1117-1121Informations de copyright
Copyright © 2021 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
Références
Mol Biol Rep. 2020 Jun;47(6):4383-4392
pubmed: 32410141
Cell Mol Immunol. 2021 Feb;18(2):487-489
pubmed: 33318629
Gynecol Endocrinol. 2018 Feb;34(2):115-119
pubmed: 28792788
Fertil Steril. 2007 Dec;88(6):1645-52
pubmed: 17418155
Eur Urol Focus. 2020 Sep 15;6(5):1124-1129
pubmed: 32563676
Fertil Steril. 2020 Jun;113(6):1135-1139
pubmed: 32482249
Fertil Steril. 2011 Jan;95(1):176-81
pubmed: 20674894
Urology. 2020 Aug;142:42
pubmed: 32343996
Fertil Steril. 2020 Jul;114(1):33-43
pubmed: 32622411
Sci Rep. 2020 Nov 18;10(1):20048
pubmed: 33208819
Front Med (Lausanne). 2021 Jan 13;7:563893
pubmed: 33521006
EClinicalMedicine. 2020 Nov;28:100604
pubmed: 33134901
Int J Antimicrob Agents. 2020 Aug;56(2):106024
pubmed: 32450197
Nat Rev Endocrinol. 2020 Jun;16(6):297-298
pubmed: 32242089
Reprod Biomed Online. 2021 Jan;42(1):260-267
pubmed: 33288478
Hum Reprod. 2005 Apr;20(4):915-22
pubmed: 15665015
J Clin Endocrinol Metab. 2020 Nov 1;105(11):
pubmed: 32770239
Am J Reprod Immunol. 2020 Nov;84(5):e13351
pubmed: 32969123
Gynecol Endocrinol. 2016 Oct;32(sup2):37-40
pubmed: 27759450
Mol Hum Reprod. 2020 Jun 1;26(6):367-373
pubmed: 32365180
Hum Reprod. 2021 Jan 25;36(2):390-394
pubmed: 32998162
Int J Mol Sci. 2020 Jun 27;21(13):
pubmed: 32604999
AIDS. 2016 Apr 24;30(7):1083-8
pubmed: 27028143